These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28326014)

  • 41. Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.
    Rueda Revilla N; Martínez-Cué C
    Antioxidants (Basel); 2020 Aug; 9(8):. PubMed ID: 32756318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome.
    Belichenko NP; Belichenko PV; Kleschevnikov AM; Salehi A; Reeves RH; Mobley WC
    J Neurosci; 2009 May; 29(18):5938-48. PubMed ID: 19420260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
    Stringer M; Goodlett CR; Roper RJ
    Mol Genet Genomic Med; 2017 Sep; 5(5):451-465. PubMed ID: 28944229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome.
    Pinto B; Morelli G; Rastogi M; Savardi A; Fumagalli A; Petretto A; Bartolucci M; Varea E; Catelani T; Contestabile A; Perlini LE; Cancedda L
    Neuron; 2020 Dec; 108(5):887-904.e12. PubMed ID: 33027640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons.
    Huo HQ; Qu ZY; Yuan F; Ma L; Yao L; Xu M; Hu Y; Ji J; Bhattacharyya A; Zhang SC; Liu Y
    Stem Cell Reports; 2018 Apr; 10(4):1251-1266. PubMed ID: 29526735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.
    Araujo BH; Torres LB; Guilhoto LM
    Epilepsy Behav; 2015 Dec; 53():120-5. PubMed ID: 26558714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome.
    Xu R; Brawner AT; Li S; Liu JJ; Kim H; Xue H; Pang ZP; Kim WY; Hart RP; Liu Y; Jiang P
    Cell Stem Cell; 2019 Jun; 24(6):908-926.e8. PubMed ID: 31130512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.
    Ruparelia A; Pearn ML; Mobley WC
    Curr Opin Neurobiol; 2012 Oct; 22(5):880-6. PubMed ID: 22658745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxyurea Improves Spatial Memory and Cognitive Plasticity in Mice and Has a Mild Effect on These Parameters in a Down Syndrome Mouse Model.
    Brose RD; Savonenko A; Devenney B; Smith KD; Reeves RH
    Front Aging Neurosci; 2019; 11():96. PubMed ID: 31139073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.
    Rueda N; Flórez J; Dierssen M; Martínez-Cué C
    Prog Brain Res; 2020; 251():245-268. PubMed ID: 32057309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
    García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
    PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GABAergic control of depression-related brain states.
    Luscher B; Fuchs T
    Adv Pharmacol; 2015; 73():97-144. PubMed ID: 25637439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome.
    Schulz JM; Knoflach F; Hernandez MC; Bischofberger J
    J Neurosci; 2019 Jun; 39(26):5210-5221. PubMed ID: 31000585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sleep impairment and reduced interneuron excitability in a mouse model of Dravet Syndrome.
    Kalume F; Oakley JC; Westenbroek RE; Gile J; de la Iglesia HO; Scheuer T; Catterall WA
    Neurobiol Dis; 2015 May; 77():141-54. PubMed ID: 25766678
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.
    Xu MY; Wong AHC
    Acta Pharmacol Sin; 2018 May; 39(5):733-753. PubMed ID: 29565038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for Down syndrome.
    Trazzi S; Fuchs C; Valli E; Perini G; Bartesaghi R; Ciani E
    J Biol Chem; 2013 Jul; 288(29):20817-20829. PubMed ID: 23740250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early environmental therapy rescues brain development in a mouse model of Down syndrome.
    Begenisic T; Sansevero G; Baroncelli L; Cioni G; Sale A
    Neurobiol Dis; 2015 Oct; 82():409-419. PubMed ID: 26244989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Identification of molecules with altered expression in the brain of mouse model for Down syndrome by comprehensive analyses].
    Ishihara K
    Yakugaku Zasshi; 2013; 133(9):989-94. PubMed ID: 23995807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mouse models for Down syndrome-associated developmental cognitive disabilities.
    Liu C; Belichenko PV; Zhang L; Fu D; Kleschevnikov AM; Baldini A; Antonarakis SE; Mobley WC; Yu YE
    Dev Neurosci; 2011; 33(5):404-13. PubMed ID: 21865664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Astrocytes in Down Syndrome Across the Lifespan.
    Ponroy Bally B; Murai KK
    Front Cell Neurosci; 2021; 15():702685. PubMed ID: 34483840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.